Novo Nordisk and Eli Lilly are eating up the entire obesity drug market
The two companies have entered mutual agreements and commitments related to development of obesity drugs for up to USD 3.5bn this year alone.
by marketwire
Novo Nordisk and archrival Eli Lilly have been busy in their shared efforts of buying up the obesity treatment medicine market, cementing each of their positions in said rapidly growing market.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
